We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics


Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
05 Nov 2020 - 07 Nov 2020

Performance Compared for Three Ebola Rapid Diagnostic Tests

By LabMedica International staff writers
Posted on 01 Oct 2020
Print article
Image: DPP Ebola Antigen System is a 15 minute rapid test for detection of Ebola Virus Specific Antigen (Photo courtesy of Chembio Diagnostic Systems).
Image: DPP Ebola Antigen System is a 15 minute rapid test for detection of Ebola Virus Specific Antigen (Photo courtesy of Chembio Diagnostic Systems).
Ebola is a rare but deadly virus that causes fever, body aches, and diarrhea, and sometimes bleeding inside and outside the body. As the virus spreads through the body, it damages the immune system and organs. Ultimately, it causes levels of blood-clotting cells to drop.

Diagnosing Ebola virus disease (EVD) shortly after infection can be difficult. Early symptoms of EVD such as fever, headache, and weakness are not specific to Ebola virus infection and often are seen in patients with other more common diseases, like malaria and typhoid fever. Polymerase chain reaction (PCR) is one of the most commonly used diagnostic methods because of its ability to detect low levels of Ebola virus.

An international team of scientists collaborating with Columbia University (New York, NY, USA) evaluated the three rapid diagnostic Tests (RDTs) in 109 Ebola-positive and 96 Ebola-negative stored serum samples collected during the outbreak in Guinea in 2014/15, and tested by real-time polymerase chain reaction (RT-PCR). Sensitivity, specificity, and overall percent agreement were calculated for each RDT using RT-PCR as a reference standard, stratified by Ct value ranges.

All tests evaluated in the study used the Dual Path Platform (DPP; Chembio Diagnostic Systems, Medford, NY, USA) technology, which consists of an immunochromatographic test cartridge and a small, battery-operated reflectance reader. The DPP Fever Panel Antigen System (the “Fever Panel Test”) is a multiplex assay detecting Plasmodium falciparum (HRP2), pan-Plasmodium (pLDH), and protein antigens specific for Lassa, Pan-Ebola (Zaire, Sudan, Bundibugyo), Marburg, Dengue, Chikungunya, and Zika Viruses. The DPP Ebola Antigen System (the “Ebola Test”) tests for Ebola Zaire antigen, and the DPP Ebola-Malaria Antigen duplex system (the “Ebola-Malaria Test”) detects Ebola Zaire antigen, Plasmodium falciparum (HRP2), and pan-Plasmodium (pLDH). All tests are qualitative and detect the VP40 antigen, which is specific to Ebola.

The investigators reported that all tests performed with high accuracy on samples with low Ct value (high viral load). The Fever Panel test performed with the highest accuracy, with a sensitivity of 89.9% and specificity of 90.6%. The Ebola and Ebola-Malaria tests performed comparably to each other: sensitivity was 77.1% and 78% respectively, and specificity was 91.7% for the Ebola test and 95.8% for the Ebola-Malaria test.

The authors concluded that their study had evaluated the accuracy of three novel rapid diagnostic tests for Ebola. The tests may have significant public health relevance, particularly the Fever Panel test, which detects seven pathogens including Ebola. Given limitations to the study resulting from uncertain sample quality, further evaluation is warranted. All tests performed with highest accuracy on samples with low Ct value (high viral load), and the data presented suggests that these RDTs may be useful for point-of-care diagnosis of cases in the context of an outbreak. The study was published on September 15, 2020 in the journal BMC Infectious Diseases.

Print article
BIOHIT  Healthcare OY


Industry News

view channel
Image: Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually (Photo courtesy of Mindray)

Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually

High-volume laboratories face several challenges, including high instrument failure rate, errors due to several manual steps, low efficiency and long TAT, and heavier workload for the lab staff.... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.